The Courier Mail | LTR hard sell not required

Following last week’s announcement of positive results from our SPONTAN® pivotal bioequivalence clinical study, LTR Pharma was featured in The Courier Mail’s City Beat by business reporter Glen Norris over the weekend. Here’s an excerpt: “LTR, which is developing an intranasal spray treatment called SPONTAN, on Friday released data that is expected to support the […]

Small Caps | LTR Pharma’s SPONTAN nasal spray achieves superior results in erectile dysfunction clinical study

LTR Pharma’s successful results from its pivotal bioequivalence clinical study have been featured in Small Caps, highlighting the positive market response to the announcement. Journalist Colin Hay wrote: ” LTR Pharma (ASX: LTP) has come out of a trading halt with the announcement of successful results from a pivotal bioequivalence clinical study into a breakthrough treatment for […]

SPONTAN® achieves positive clinical study results

LTR Pharma (ASX:LTP) has announced extremely positive results from its SPONTAN® pivotal bioequivalence clinical study. Initial analysis has concluded that SPONTAN® achieves rapid absorption and faster onset of action compared to oral PDE5 inhibitors.  The results demonstrated that SPONTAN achieves rapid absorption and faster onset of action at a substantially lower dose, compared to traditional […]

Livewire | LTR Pharma – ED & the need for speed

LTR Pharma and SPONTAN have been featured on Livewire Markets in an artucle titled “ED & the need for speed.” In the article, author Thomas Schoenmaker of Alpine Capital presents the market opportunity for innovation in the ED space, and how LTR Pharma is placed to take advantage of this position with SPONTAN. Here’s an […]

Conversation Series | 101 on Erectile Dysfunction

The second episode of the LTR Pharma Conversation Series is now live. This week, Professor Chung shares insights into Erectile Dysfunction (ED); an explanation of the erectile mechanism; how ED is caused; who it impacts (this one might surprise you); and the potential for SPONTAN® to help those with men’s health issues.  

Conversation Series | Meet The Expert – Professor Eric Chung

The first episode of the LTR Pharma Conversation Series is now live.  This week, we introduce to you Professor Eric Chung, LTR Pharma Scientific and Clinical Advisor and a consultant urological surgeon. Meet the Expert: Professor Chung is a consultant urological surgeon at the AndroUrology Centre for Sexual, Urinary and Reproductive Excellence and holds professorial […]

Body + Soul | Interview with Professor Eric Chung

LTR Pharma Scientific and Clinical Advisor and consultant urological surgeon, Professor Eric Chung shares insights with Body + Soul to discuss the correlation between performance anxiety and infidelity. In this latest feature, Professor Eric Chung, unpacks the effects of cheating on both partners (the cheater and the cheated) and provides guidance for navigating the aftermath […]

Men’s Health Australia | Interview with Professor Eric Chung

LTR Pharma Scientific and Clinical Advisor and consultant urological surgeon, Professor Eric Chung was recently interviewed by Cayle Reid at Men’s Health Australia to discuss external factors that can influence performance in the bedroom. Professor Chung commented: “Sex is about emotional and physical satisfaction, and both factors can play a significant role in our sexual […]

Quarterly Activities Report and 4C – period ended 31 March 2024

LTR Pharma has today released its Quarterly Activities Report and Appendix 4C Quarterly Cash Flow report for the quarter ended 31 March 2024. Key highlights from this period include: Pivotal clinical study of SPONTAN® fully recruited and completed dosing of all participants. SPONTAN achieved key manufacturing validation and first commercial batch production. SPONTAN is designed […]

SPONTAN® pivotal clinical study completes recruitment and dosing

LTR Pharma has today announced that all patients recruited for its pivotal bioequivalence clinical study of SPONTAN® nasal spray have now received their second and final dose, completing the recruitment and dosing stage of the clinical study. The Study is evaluating the relative bioavailability of SPONTAN, a novel and proprietary PDE5 nasal spray treatment compared […]

Ausbiz | Interview with Lee Rodne

This week, LTR Pharma’s Executive Chairman, Lee Rodne, spoke with Juliette Saly from ausbiz to discuss the Company’s progress in the advancement of rapid treatment for Erectile Dysfunction (ED), SPONTAN®, including the commencement of recruitment for its pivotal bioequivalence study. Take a look:

First patients dosed for SPONTAN® bioequivalence clinical study

LTR Pharma is pleased to announce the commencement of patient dosing in the Company’s pivotal bioequivalence clinical study of SPONTAN® nasal spray. The clinical study will assess the relative bioavailability of SPONTAN, a novel and proprietary PDE5 nasal spray treatment for ED. This first-in-kind nasal spray will be compared to oral administration of Vardenafil, a […]

ASX:LTP Half Year Financial Report

LTR Pharma has today released its Half Year Financial Report for the period ended 31 December 2023. This has been a defining period for the Company, marked by a successful ASX debut on 11 December 2023, and rapid progress towards our pivotal bioequivalence study. Key highlights include:  Successfully completed an oversubscribed IPO. The Company listed […]

Stockhead | ASX stocks striving to inject youthfulness into an aging world population

LTR Pharma’s innovative nasal spray for erectile dysfunction, SPONTAN is featured in a Stockhead article by Nadine McGrath titled “ASX stocks striving to inject youthfulness into an aging world population” The article highlights the investment opportunities in ASX-listed companies that are addressing issues associated with longevity and the ageing population. “LTP executive director Lee Rodne […]

Clinical Trials Arena | LTR Pharma begins recruitment in study of nasal spray for ED

News that LTR Pharma’s pivotal clinical trial is set to begin has been reported in Clinical Trials Arena. An excerpt: “The trial will take place in Sydney, Australia, in partnership with Southern Star Research and Scientia Clinical Research. It will be conducted under the supervision of staff from Scientia Clinical Research, while Southern Star Research will […]

BNNBreaking | Revolutionary Nasal Spray for Erectile Dysfunction: SPONTAN® Clinical Trial Begins

BNN Breaking has published the news that LTR Pharma has initiated enrolment of patients for its pivotal bioequivalence clinical trial of the nasal spray treatment, SPONTAN®. An excerpt: “The implications of SPONTAN®’s success extend far beyond the realm of erectile dysfunction. A positive outcome from the trial could set the stage for regulatory approval from heavyweights […]

Stockhead | LTR Pharma firms up study for erectile dysfunction with patient recruitment

LTR Pharma has been featured in Stockhead following the announcement that patient recruitment for its pivotal clinical study of SPONTAN® has opened. An excerpt: “The global ED market is forecast to increase to US$5.94 billion by 2028, growing at a CAGR of 7.1%. With such strong demand for effective ED treatments, LTP hit the Aussie bourse […]

Patient Recruitment Commences for SPONTAN® Pivotal Clinical Study

LTR Pharma has today announced patient recruitment has commenced for its pivotal bioequivalence clinical study for SPONTAN®, a fast-acting, on-demand Nasal Spray treatment for Erectile Dysfunction (ED). The Study will assess the relative bioavailability of Vardenafil following administration of SPONTAN nasal spray, when compared to oral delivery of Vardenafil tablets – a widely used PDE5 […]